Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts give Tango Therapeutics a consensus rating of Moderate Buy from 12 firms (10 buys, 1 hold, 1 sell) with an average 1‑year price target of $20.67, and several brokers recently raised targets (e.g., Stifel to $24, Guggenheim to $20, Mizuho to $20).
• The stock opened at $25.75 and trades well above its 50‑day ($18.60) and 200‑day ($12.81) averages, has a $3.71 billion market cap and a one‑year range of $1.03–$28.41, but the company remains unprofitable (reported EPS -$0.29 beating -$0.31; consensus expects -$1.34 this year).
• Insider selling totaled 211,344 shares (~$3.5M) last quarter, while institutional investors own 78.99% of the stock with large position increases from firms like Adage, Goldman Sachs and Logos.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $20.6667.

A number of research firms have recently commented on TNGX. Stifel Nicolaus boosted their price target on Tango Therapeutics from $15.00 to $24.00 and gave the stock a "buy" rating in a report on Monday, March 9th. Jefferies Financial Group reissued a "buy" rating and set a $18.00 price target on shares of Tango Therapeutics in a report on Thursday, March 5th. Guggenheim boosted their price target on Tango Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Friday, March 6th. Wedbush boosted their price target on Tango Therapeutics from $15.00 to $19.00 and gave the stock an "outperform" rating in a report on Friday, March 6th. Finally, Mizuho boosted their price target on Tango Therapeutics from $19.00 to $20.00 and gave the stock an "outperform" rating in a report on Wednesday, March 11th.

Tango Therapeutics Price Performance

Tango Therapeutics stock opened at $25.75 on Friday. The stock's fifty day moving average price is $18.60 and its two-hundred day moving average price is $12.81. Tango Therapeutics has a one year low of $1.03 and a one year high of $28.41. The firm has a market cap of $3.71 billion, a PE ratio of -29.60 and a beta of 1.31.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. Sell-side analysts expect that Tango Therapeutics will post -1.34 earnings per share for the current fiscal year.

Insider Transactions at Tango Therapeutics

In other news, insider Adam Crystal sold 54,345 shares of the business's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $12.77, for a total transaction of $693,985.65. Following the completion of the transaction, the insider owned 132,873 shares of the company's stock, valued at approximately $1,696,788.21. The trade was a 29.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Barbara Weber sold 30,519 shares of the business's stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $374,162.94. Following the sale, the director owned 1,629,254 shares in the company, valued at $19,974,654.04. This represents a 1.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 211,344 shares of company stock valued at $3,499,842. Corporate insiders own 7.50% of the company's stock.

Institutional Investors Weigh In On Tango Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TNGX. Adage Capital Partners GP L.L.C. grew its position in Tango Therapeutics by 322.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company's stock worth $93,986,000 after acquiring an additional 8,096,924 shares during the last quarter. Caligan Partners LP bought a new stake in Tango Therapeutics during the 4th quarter worth $33,047,000. Goldman Sachs Group Inc. grew its position in Tango Therapeutics by 227.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 4,942,414 shares of the company's stock worth $43,790,000 after acquiring an additional 3,432,939 shares during the last quarter. Logos Global Management LP grew its position in Tango Therapeutics by 342.1% during the 4th quarter. Logos Global Management LP now owns 4,200,000 shares of the company's stock worth $37,212,000 after acquiring an additional 3,250,000 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP bought a new stake in Tango Therapeutics during the 3rd quarter worth $25,924,000. Institutional investors own 78.99% of the company's stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.